Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies

Clinical Immunology

Volumn 141, Issue 2, 2011, Pages 218-227

  Qiu, Xiangguo ^a   Alimonti, Judie B ^a,c   Melito, P Leno ^a   Fernando, Lisa ^a   Ströher, Ute ^a,c,d   Jones, Steven M ^a,b,c,e  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b Department of Immunology ^*  (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^e Cognoveritas Consulting Inc ^*  (Canada)

Author keywords

Ebola virus; Epitope; Glycoprotein; Monoclonal antibodies; Vesicular stomatitis virus; Virus

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY; MUCIN; VIRUS GLYCOPROTEIN;

ANTIGEN BINDING; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL FUSION; CONTROLLED STUDY; EBOLA VIRUS; FEMALE; HYBRIDOMA; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN SECRETION; SURVIVAL RATE; VIRUS INFECTION; VIRUS RECOMBINANT; ZAIRE EBOLAVIRUS;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; ANTIGENS, VIRAL; BLOTTING, WESTERN; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; EBOLAVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HEMORRHAGIC FEVER, EBOLA; HUMANS; HYBRIDOMAS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; IMMUNOPRECIPITATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROTEIN STRUCTURE, TERTIARY; VIRAL ENVELOPE PROTEINS;

EID: 80054837546     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.08.008     Document Type: Article

References (47)

1. Sanchez A., Geisbert T.W., Feldmann H. Filoviridae: Marburg and Ebola viruses. Fields Virology 2007, 1409-1448. Lippincott, Williams & Wilkins. 5th ed. D.M. Knipe, P.M. Howley, D.E. Griffin, R.A. Lamb, M.A. Martin, B. Roizman, S.E. Straus (Eds.).
2. Towner J.S., Sealy T.K., Khristova M.L., Albarino C.G., Conlan S., Reeder S.A., Quan P.L., Lipkin W.I., Downing R., Tappero J.W., Okware S., Lutwama J., Bakamutumaho B., Kayiwa J., Comer J.A., Rollin P.E., Ksiazek T.G., Nichol S.T. Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog. 2008, 4:e1000212.
3. Feldmann H., Geisbert T.W. Ebola haemorrhagic fever. Lancet 2011, 377:849-862.
4. Yang Z.Y., Duckers H.J., Sullivan N.J., Sanchez A., Nabel E.G., Nabel G.J. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat. Med. 2000, 6:886-889.
5. Feldmann H., Volchkov V.E., Volchkova V.A., Klenk H.D. The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis. Arch. Virol. Suppl. 1999, 15:159-169.
6. Feldmann H., Volchkov V.E., Volchkova V.A., Stroher U., Klenk H.D. Biosynthesis and role of filoviral glycoproteins. J. Gen. Virol. 2001, 82:2839-2848.
7. Alazard-Dany N., Volchkova V., Reynard O., Carbonnelle C., Dolnik O., Ottmann M., Khromykh A., Volchkov V.E. Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level. J. Gen. Virol. 2006, 87:1247-1257.
8. Yonezawa A., Cavrois M., Greene W.C. Studies of ebola virus glycoprotein-mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha. J. Virol. 2005, 79:918-926.
9. Wahl-Jensen V.M., Afanasieva T.A., Seebach J., Stroher U., Feldmann H., Schnittler H.J. Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J. Virol. 2005, 79:10442-10450.
10. Volchkov V.E., Volchkova V.A., Muhlberger E., Kolesnikova L.V., Weik M., Dolnik O., Klenk H.D. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 2001, 291:1965-1969.
11. Simmons G., Wool-Lewis R.J., Baribaud F., Netter R.C., Bates P. Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J. Virol. 2002, 76:2518-2528.
12. Jahrling P.B., Geisbert J.B., Swearengen J.R., Larsen T., Geisbert T.W. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J. Infect. Dis. 2007, 196(Suppl 2):S400-S403.
13. Maruyama T., Rodriguez L.L., Jahrling P.B., Sanchez A., Khan A.S., Nichol S.T., Peters C.J., Parren P.W., Burton D.R. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J. Virol. 1999, 73:6024-6030.
14. Oswald W.B., Geisbert T.W., Davis K.J., Geisbert J.B., Sullivan N.J., Jahrling P.B., Parren P.W., Burton D.R. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog 2007, 3:e9.
15. Wilson J.A., Hevey M., Bakken R., Guest S., Bray M., Schmaljohn A.L., Hart M.K. Epitopes involved in antibody-mediated protection from Ebola virus. Science 2000, 287:1664-1666.
16. Baize S., Leroy E.M., Georges-Courbot M.C., Capron M., Lansoud-Soukate J., Debre P., Fisher-Hoch S.P., McCormick J.B., Georges A.J. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat. Med. 1999, 5:423-426.
17. Ksiazek T.G., Rollin P.E., Williams A.J., Bressler D.S., Martin M.L., Swanepoel R., Burt F.J., Leman P.A., Khan A.S., Rowe A.K., Mukunu R., Sanchez A., Peters C.J. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J. Infect. Dis. 1999, 179(Suppl 1):S177-S187.
18. Jones S.M., Stroher U., Fernando L., Qiu X., Alimonti J., Melito P., Bray M., Klenk H.D., Feldmann H. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J. Infect. Dis. 2007, 196(Suppl 2):S404-S412.
19. Gupta M., Mahanty S., Bray M., Ahmed R., Rollin P.E. Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. J. Virol. 2001, 75:4649-4654.
20. Jones S.M., Feldmann H., Stroher U., Geisbert J.B., Fernando L., Grolla A., Klenk H.D., Sullivan N.J., Volchkov V.E., Fritz E.A., Daddario K.M., Hensley L.E., Jahrling P.B., Geisbert T.W. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 2005, 11:786-790.
21. Warfield K.L., Swenson D.L., Olinger G.G., Kalina W.V., Aman M.J., Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J. Infect. Dis. 2007, 196(Suppl 2):S430-S437.
22. Richardson J.S., Yao M.K., Tran K.N., Croyle M.A., Strong J.E., Feldmann H., Kobinger G.P. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS One 2009, 4:e5308.
23. Wilson J.A., Bray M., Bakken R., Hart M.K. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology 2001, 286:384-390.
24. Bukreyev A., Rollin P.E., Tate M.K., Yang L., Zaki S.R., Shieh W.J., Murphy B.R., Collins P.L., Sanchez A. Successful topical respiratory tract immunization of primates against Ebola virus. J. Virol. 2007, 81:6379-6388.
25. Dowling W., Thompson E., Badger C., Mellquist J.L., Garrison A.R., Smith J.M., Paragas J., Hogan R.J., Schmaljohn C. The influences of glycosylation on the antigenicity, immunogenicity, and protective efficacy of Ebola virus GP DNA vaccines. J. Virol. 2006, 81:1821-1837.
26. Qiu X., Fernando L., Alimonti J.B., Melito P.L., Feldmann F., Dick D., Stroher U., Feldmann H., Jones S.M. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One 2009, 4:e5547.
27. Volchkov V.E., Volchkova V.A., Dolnik O., Feldmann H., Klenk H.D. Polymorphism of filovirus glycoproteins. Adv. Virus Res. 2005, 64:359-381.
28. Sanchez A., Trappier S.G., Mahy B.W., Peters C.J., Nichol S.T. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:3602-3607.
29. Wahl-Jensen V., Kurz S.K., Hazelton P.R., Schnittler H.J., Stroher U., Burton D.R., Feldmann H. Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J. Virol. 2005, 79:2413-2419.
30. Falzarano D., Krokhin O., Van Domselaar G., Wolf K., Seebach J., Schnittler H.J., Feldmann H. Ebola sGP-the first viral glycoprotein shown to be C-mannosylated. Virology 2007, 368:83-90.
31. Falzarano D., Krokhin O., Wahl-Jensen V., Seebach J., Wolf K., Schnittler H.J., Feldmann H. Structure-function analysis of the soluble glycoprotein, sGP, of Ebola virus. ChemBioChem 2006, 7:1605-1611.
32. Shahhosseini S., Das D., Qiu X., Feldmann H., Jones S.M., Suresh M.R. Production and characterization of monoclonal antibodies against different epitopes of Ebola virus antigens. J. Virol. Methods 2007, 143:29-37.
33. Takada A., Ebihara H., Feldmann H., Geisbert T.W., Kawaoka Y. Epitopes required for antibody-dependent enhancement of Ebola virus infection. J. Infect. Dis. 2007, 196(Suppl 2):S347-S356.
34. Takada A., Ebihara H., Jones S., Feldmann H., Kawaoka Y. Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine 2007, 25:993-999.
35. Lucht A., Grunow R., Otterbein C., Moller P., Feldmann H., Becker S. Production of monoclonal antibodies and development of an antigen capture ELISA directed against the envelope glycoprotein GP of Ebola virus. Med. Microbiol. Immunol. 2004, 193:181-187.
36. Parren P.W., Geisbert T.W., Maruyama T., Jahrling P.B., Burton D.R. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J. Virol. 2002, 76:6408-6412.
37. Shedlock D.J., Bailey M.A., Popernack P.M., Cunningham J.M., Burton D.R., Sullivan N.J. Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. Virology 2010, 401:228-235.
38. Takada A., Feldmann H., Stroeher U., Bray M., Watanabe S., Ito H., McGregor M., Kawaoka Y. Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J. Virol. 2003, 77:1069-1074.
39. Feldmann H., Jones S.M., Daddario-Dicaprio K.M., Geisbert J.B., Stroher U., Grolla A., Bray M., Fritz E.A., Fernando L., Feldmann F., Hensley L.E., Geisbert T.W. Effective post-exposure treatment of Ebola infection. PLoS Pathog. 2007, 3:e2.
40. Garbutt M., Liebscher R., Wahl-Jensen V., Jones S., Moller P., Wagner R., Volchkov V., Klenk H.D., Feldmann H., Stroher U. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J. Virol. 2004, 78:5458-5465.
41. Das D., Jacobs F., Feldmann H., Jones S.M., Suresh M.R. Differential expression of the Ebola virus GP(1,2) protein and its fragments in E. coli. Protein Expr. Purif. 2007, 54:117-125.
42. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
43. Davis J.M., Pennington J.E., Kubler A.M., Conscience J.F. A simple, single-step technique for selecting and cloning hybridomas for the production of monoclonal antibodies. J. Immunol. Methods 1982, 50:161-171.
44. Marasco W.A., Sui J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat. Biotechnol. 2007, 25:1421-1434.
45. Prabhu N., Prabakaran M., Ho H.T., Velumani S., Qiang J., Goutama M., Kwang J. Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. J. Virol. 2009, 83:2553-2562.
46. Bray M., Davis K., Geisbert T., Schmaljohn C., Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 1998, 178:651-661.
47. Bossart K.N., Zhu Z., Middleton D., Klippel J., Crameri G., Bingham J., McEachern J.A., Green D., Hancock T.J., Chan Y.P., Hickey A.C., Dimitrov D.S., Wang L.F., Broder C.C. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog. 2009, 5:e1000642.